Brii Biosciences Launches Amubarvimab/Romlusevimab Combination in China for the Treatment of COVID-19
Shots: Brii Bio launched amubarvimab + romlusevimab in China as a long-acting COVI...
Oxford Biomedica Signs Three Year Master Services & Development Agreement with Astrazeneca to Manufacture COVID-19 Vaccines
Shots: The companies have entered into a 3yr. agreement to manufacture AstraZeneca...
Pfizer Reports NDA Submission of Paxlovid to the US FDA for the Treatment of COVID-19
Shots: The NDA was submitted based on the P-II/III (EPIC-HR) & (EPIC-SR) trial...
Sanofi and GSK Report Results of COVID-19 Vaccine in the P-III (VAT08) Trial Against Omicron
Shots: The P-III (VAT08) trial evaluated an adjuvanted bivalent D614 & B...
Clover Reports the First Patient Dosing of SCB-2019 as a Heterologous Booster in P-III Trial for the Treatment of COVID-19
Shots: The first patient has been dosed in a P-III study evaluating SCB-2019 (CpG...
Pfizer and BioNTech Report EUA Expansion for Booster Dose of COVID-19 Vaccine in Children Aged 5 Through 11 Years
Shots: The EUA was based on the P-II/III trial to evaluate the 10µg booster...
